摘要
目的:评估门诊2型糖尿病(T2DM)患者口服降糖药物应用及主要代谢指标控制达标情况。方法:随机调查347例口服药物治疗的门诊T2DM患者,收集患者的人口学资料、口服降糖药物应用及血糖、血压、血脂等指标,并分析慢性并发症发生情况。根据《中国2型糖尿病防治指南》(2010年版)分析代谢指标达标情况。结果:347例患者中口服降糖药物使用比例最高的为二甲双胍(52.2%),其次为磺脲类(51.6%)。治疗方案中单药治疗占35.2%,2种及3种以上药物分别占49.0%及15.8%。糖化血红蛋白(HbA1c)、空腹血糖、餐后血糖的达标率分别为59.1%,73.2%,71.8%。33.4%的患者血压达标,各血脂指标仅有40%患者达标。患者用药种类随糖尿病病程延长而增加,而单药、两药及三药治疗的患者HbA1c水平无差异。结论:根据《中国2型糖尿病防治指南》(2010年版),门诊T2DM患者血糖达标率明显提高,但血压、血脂达标率较低,仍有40.9%的患者血糖未能满意控制。
OBJECTIVE To assess the status of oral antidiabetic drugs （OADs） and metabolic indicators in outpatient patients with type 2 diabetes. METHODS This survey recruited 347 case of type 2 diabetic patients receiving oral antidiabetic agents randomly. Demographic data, treatment, blood glucose, blood pressure, lipid profile and chronic complications were collected through outpatient interview and case history investigation. Target profiles of various metabolic indicators were analyzed according to the Chinese Guideline on Prevention and Treatment of Type 2 Diabetes （2010）. RESULTS Metformin was the most frequently used OAD （55. 2%）, followed by sulfonylurea （51.6%）. For therapeutic protocols, 35.2%of patients wereundertaking the single OAD treatment, while 49. 0% of patients with two kinds of OAD and 15.8 % with three kinds or more. The targeted rates of HbAlc, fasting and postprandial plasma glucose were 59. 1%,73. 2% and 71.8% respectively. Totally 33. 4% of patients were up to the targeted standard of blood pressure, and only 40% of them were up to the targeted standardof lipid profile. The number of OADs was increased along with the duration of diabetes. HbAlc was comparable between patients treated with single, two kinds and three kinds of OADs. CONCLUSION According to the latest Chinese Guideline on Prevention and Treatment of Type 2 Diabetes （2010）, the targeted rates of blood glucose increased significantly among our outpatient type 2 diabetic patients, but the targeted rates of blood pressure and lipid profile were still lower. There have been still40. 9% of patients far from the guiding standard.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第5期364-368,共5页
Chinese Journal of Hospital Pharmacy
关键词
2型糖尿病
口服降糖药物
血糖控制
并发症
type 2 diabetes
oral antidiabetic drug
glycemic control
complications
